文章：

新型全球免疫-营养-炎症指数（GINI）对接受同步放化疗的IIIC期非小细胞肺癌患者的预后价值

The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

原文发布日期：11 September 2023

DOI: 10.3390/cancers15184512

类型: Article

开放获取: 是

英文摘要：

Background: We sought to determine the prognostic value of the newly developed Global Immune-Nutrition-Inflammation Index (GINI) in patients with stage IIIC non-small cell lung cancer (NSCLC) who underwent definitive concurrent chemoradiotherapy (CCRT). Methods: This study was conducted on a cohort of 802 newly diagnosed stage IIIC NSCLC patients who underwent CCRT. The novel GINI created first here was defined as follows: GINI = [C-reactive protein × Platelets × Monocytes × Neutrophils] ÷ [Albumin × Lymphocytes]. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal pre-CCRT GINI cut-off value that substantially interacts with the locoregional progression-free (LRPFS), progression-free (PFS), and overall survival (OS). Results: The optimal pre-CCRT GINI cutoff was 1562 (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). Patients presenting with a GINI ≥ 1562 had substantially shorter median LRPFS (13.3 vs. 18.4 months;p< 0.001), PFS (10.2 vs. 14.3 months;p< 0.001), and OS (19.1 vs. 37.8 months;p< 0.001) durations than those with a GINI < 1562. Results of the multivariate analysis revealed that the pre-CCRT GINI ≥ 1562 (vs. <1562), T4 tumor (vs. T3), and receiving only 1 cycle of concurrent chemotherapy (vs. 2–3 cycles) were the factors independently associated with poorer LRPS (p< 0.05 for each), PFS (p< 0.05 for each), and OS (p< 0.05 for each). Conclusion: The newly developed GINI index efficiently divided the stage IIIC NSCLSC patients into two subgroups with substantially different median and long-term survival outcomes.

摘要翻译： 

背景：本研究旨在评估新构建的全球免疫-营养-炎症指数（GINI）对接受根治性同步放化疗（CCRT）的IIIC期非小细胞肺癌（NSCLC）患者的预后预测价值。方法：本研究纳入802例初诊IIIC期NSCLC并行CCRT治疗的患者队列。首次构建的GINI计算公式为：GINI = [C反应蛋白 × 血小板 × 单核细胞 × 中性粒细胞] ÷ [白蛋白 × 淋巴细胞]。采用受试者工作特征（ROC）曲线分析确定与局部区域无进展生存期（LRPFS）、无进展生存期（PFS）及总生存期（OS）显著相关的最佳CCRT前GINI截断值。结果：CCRT前GINI最佳截断值为1562（曲线下面积：76.1%；敏感度：72.4%；特异度：68.2%；约登指数：0.406）。GINI ≥ 1562患者的中位LRPFS（13.3 vs. 18.4个月；p<0.001）、PFS（10.2 vs. 14.3个月；p<0.001）及OS（19.1 vs. 37.8个月；p<0.001）均显著短于GINI < 1562患者。多因素分析显示，CCRT前GINI ≥ 1562（对比<1562）、T4分期肿瘤（对比T3）以及仅接受1周期同步化疗（对比2-3周期）是LRPFS（各项p<0.05）、PFS（各项p<0.05）和OS（各项p<0.05）的独立不良预后因素。结论：新构建的GINI指数能有效将IIIC期NSCLC患者划分为具有显著差异中位及长期生存结局的两个亚组。

原文链接：

The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy